NCT05257954 Frailty in Patient Undergoing Percutaneous Left Atrial Appendage Closure.
| NCT ID | NCT05257954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Josep Rodes-Cabau |
| Condition | Transcatheter Left Atrial Appendage Closure |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-03-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the prevalence and severity of frailty in patients undergoing LAAC, as well as its association to peri-procedural and long-term outcomes and quality of life.
Eligibility Criteria
Inclusion Criteria: * Transcatheter LAAC with any approved device * Age ≥18 years old Exclusion Criteria: * Unable to provide informed consent * Severe neuropsychiatric impairment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05257954 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transcatheter Left Atrial Appendage Closure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05257954 currently recruiting?
Yes, NCT05257954 is actively recruiting participants. Contact the research team at josep.rodes@criucpq.ulaval.ca for enrollment information.
Where is the NCT05257954 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT05257954 clinical trial?
NCT05257954 is sponsored by Josep Rodes-Cabau. The trial plans to enroll 500 participants.